Skip to main content

Phoebe Mounts

Equibles does not estimate personal net worth.

About Phoebe Mounts

Earlier roles on record: General Counsel at CorMedix Inc. (CRMD) until December 12, 2023. CorMedix Inc. reported in an 8-K filed December 15, 2023 that Phoebe Mounts was terminated as Executive Vice President, effective December 31, 2023. CorMedix Inc. reported in an 8-K filed December 15, 2023 that Phoebe Mounts was terminated as General Counsel and Corporate Secretary, effective December 12, 2023. The proxy statement of CorMedix Inc. reports total compensation of $1,254,582 for Phoebe Mounts in fiscal 2023, including a base salary of $375,000. Disclosed compensation is on record for 5 fiscal years. Phoebe Mounts has spoken on 14 earnings calls across 1 company, most recently for CorMedix Inc. on November 14, 2023. The companies whose calls Phoebe Mounts spoke on are classified in the Healthcare sector.

“the Board of Directors of the Company (the “Board”) approved the separation of employment of Dr. Mounts, effective December 31, 2023 (the “Termination Date”).”
CorMedix Inc. Form 8-K, filed December 15, 2023 · Read the filing
“Dr. Mounts will cease to hold the title of General Counsel and Corporate Secretary effective December 12, 2023.”
CorMedix Inc. Form 8-K, filed December 15, 2023 · Read the filing

Phoebe Mounts on recent calls

“I would like to thank and congratulate everyone on the teams who have worked so hard towards preparation of the CDMO site for a preapproval inspection, as well as in responding to all other requests by the FDA for information on the DefenCath NDA resubmission.”
General Counsel, CorMedix Inc. Q3 FY2023 Earnings Call ·
“As Joe mentioned, following the resubmission of the DefenCath NDA, the FDA accepted the application for review and granted a target action date of November 15, 2023.”
General Counsel, CorMedix Inc. Q2 FY2023 Earnings Call ·
“First, I would like to start by expressing my gratitude to the technical and regulatory team that has worked diligently to prepare to resubmit the DefenCath NDA as soon as possible.”
General Counsel, CorMedix Inc. Q1 FY2023 Earnings Call ·
“As you know, CorMedix received a complete response letter, or CRL, in August of 2022 in which the FDA stated that deficiencies identified during FDA inspections of our primary contract manufacturing organization and at our primary Heparin API supplier required satisfactory resolution before the DefenCath NDA may be…”
General Counsel, CorMedix Inc. Q4 FY2022 Earnings Call ·
“As we discussed on our last earnings call, the company received a complete response letter, or CRL, in August which noted no product-related issues or deficiencies in the new drug application; however, the CRL stated that the NDA could not be approved in its present form until successful remediation of compliance…”
General Counsel, CorMedix Inc. Q3 FY2022 Earnings Call ·

Affiliation history

Company network

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2023 CorMedix Inc. (CRMD) $375,000 $1,254,582
2022 CorMedix Inc. (CRMD) $375,000 $1,010,481
2021 CorMedix Inc. (CRMD) $375,000 $1,613,097
2020 CorMedix Inc. (CRMD) $350,000 $931,148
2019 CorMedix Inc. (CRMD) $232,885 $746,154

Recent activity